viking therapeutics dark horse glp-1 could be a new winner in the space Viking's Weight Loss Drug Challenges

Our goal is to help providers access compounds sourced through established pharmacy and laboratory channels

Day and colleagues were the first group to use a series of modifications to the C-terminal portion of the glucagon sequence to increase GLP-1R potency, combined with PEGylation to generate two PEGylated peptides with adequate co-agonist properties, one unbalanced towards GLP-1R, and the other a near-balanced agonist at both GLP-1R and GCGR

This medical relationship provides several benefits: Baseline assessment: Before starting any protocol, proper bloodwork establishes baseline hormone levels, organ function, and overall health status

Expected appearance: Clear, colorless, particulate-free solution

doi: 10.31083/j.jin2102073 291 PinoA.GiuntaG.RandazzoC